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Table S1.  Recruitment and Follow-Up by Cohort.  
Catchment Area  Sampling Frame  
Recruitment  
PR 
(%)  
N° of Participants  
 
Follow-Up  
Timeline  
(Years)  
Invitation  In Database  Analyzed  
Last 
Follow-Up  
(Year)  
Median in Years  
(5–95% Percentile 
Interval)  
Ohasama, Iwate, Japan  People aged ≥40 years  1988–1994  Address list  78  1535  1326  2015  22.0 (5.0–26.8)  
JingNing, Zhejiang, China  Family-based random sample  2003–2003  All villagers invited  62  895  855  2012  4.0 (3.5–7.6)  
Oktyabrsky, Novosibirsk, 
Russian Federation  
Family-based random sample  1999–2001  Address list  68  306  300  2009  16.4 (8.1–17.5)  
Niepolomice, Kraków, Poland  Family-based random sample  1999–2008  Address list  54  413  389  2014  13.5 (6.1–14.3)  
Gdańsk, Poland  Family-based random sample  2008–2010  Address list  90  289  284  2014  6.1 (4.8–8.7)  
Pilsen, Czech Republic  Family-based random sample  2000–2001  Address list  82  174  169  2015  14.1 (13.8–14.4)  
Padova, Italy  Family-based random sample  1999–2007  Address list  73  314  314  2013  13.3 (12.6–14.5)  
Noordkempen, Belgium  Family-based random sample  1985–2008  Address list  78  2904  1436  2016  24.5 (8.6–27.8)  
Uppsala, Sweden  Men aged 69–74 years  1991–1995  Population census  73  1143  1110  2015  15.1 (3.5–23.0)  
Copenhagen County, 
Denmark  
Stratified random sample of 
women and men aged 30, 40, 
50 and 60 years  
1993–1997  Population registry  83  2311  2148  2010  16.3 (5.1–17.3)  
Dublin, Ireland  
Bank employees working at 
branches across Ireland  
1989–1991  All invited  14  981  946  2007  17.6 (16.4–18.2)  
Maracaibo, Venezuela  City residents aged ≥55 years  1998–2008  Population census  71  604  590  2012  8.1 (1.7–13.7)  
Montevideo, Uruguay  Age-stratified random sample  1995–1998  
Members of a health 
insurance organization  
78  1859  1729  2007  9.0 (4.2–10.7)  
PR denotes participation rate.  The European Project on Genes in Hypertension included participants recruited in Novosibirsk, Kraków, Gdańsk, Pilsen and Padova.  Participants from Padova 
were recruited in Mirano in the province of Venice and in Torrebelvicino and Valli del Pasubio in the province of Vicenza, Italy.    
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Table S2.  Literature Sources Documenting Methods in Each Cohort.    
Study Location  Study Name  References   
Ohasama, Iwate, Japan  Ohasama Study of Blood Pressure  1-4  
China, Zhejiang, JingNing   JingNing Population Study (JNPS)  5-7  
Oktyabrsky, Novosibirsk, Russia  European Project on Genes in Hypertension (EPOGH)  8-11  
Poland, Kraków, Niepolomice   European Project on Genes in Hypertension (EPOGH)  8-10  
Poland, Gdańsk  European Project on Genes in Hypertension (EPOGH)  8-10  
Czech Republic, Pilsen   European Project on Genes in Hypertension (EPOGH)  8-10  
Italy, Padova   European Project on Genes in Hypertension (EPOGH)  8-10  
Belgium, Noordkempen   Flemish Study on Environment Genes and Health Outcomes (FLEMENGHO)  9,12-14  
Uppsala, Sweden  Uppsala Longitudinal Study of Adult Men (ULSAM)  15,16  
Copenhagen County, Denmark  Monitoring of trends and determinants in Cardiovascular Disease (MONICA)  17-19  
Dublin, Ireland  The Allied Irish Bank Study   20-21  
Maracaibo, Venezuela  Maracaibo Aging Study   22,23  
Uruguay, Montevideo   Asociación Española Primera de Socorros Mutuos Study  24,25  
References are listed starting on pages S17-S20.   
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Table S3.  Ambulatory Blood Pressure Monitoring Devices by Cohort.    
Study Cohorts  
N° of  
Participants   
Monitoring Device  
Programmed 
Intervals between 
Readings in 
Minutes   
N° of Readings Recorded over 24-Hours   
Day  Night  Programmed  Median  P5  P25  P75  P95  
Ohasama, Iwate, Japan  1326  ABP-630, Nippon Colin  30  30   48  45  36  42  48  50  
JingNing, Zhejiang, China  855  90207, SpaceLabs  20  45   65  56  48  55  57  62  
Oktyabrsky, Novosibirsk, Russia  300  90202, SpaceLabs  15  30   76  71  56  65  75  78  
Niepolomice, Kraków, Poland  389  90202, SpaceLabs  15  30   76  74  54  63 77  79  
Gdańsk, Poland  284  TM-2430, A&D  20  45   65  62  50  59  64  64  
Pilsen, Czech Republic  169  90202, SpaceLabs  20  45   65  76  54  71  80  82  
Padova, Italy  314  90202, SpaceLabs  15  30   76  76  64  74  76  125  
Noordkempen, Belgium  1436  90202, SpaceLabs  20  40   55  53  37  41  56  58  
Uppsala, Sweden  1110  Accutracker II  20–30  20–60   41–72  65  44  52  75  84  
Copenhagen County, Denmark  2148  TM-2421, A&D  15  30   80  80  67  78  81  83  
Dublin, Ireland  946  90202 and 90207, Spacelabs  30  30   48  46  37  44  48  49  
Maracaibo, Venezuela  590  90207, SpaceLabs  15  30   80  67  51  61  71  77  
Montevideo, Uruguay  1729  90207, SpaceLabs  20  40   60  37  26  33  39  42  
The TM-2421 and TM-2430 monitors implemented both an auscultatory and an oscillometric technique.  However, only oscillometric readings were used for analysis.  All devices had passed 
validation.  In cohorts with a greater number than programmed readings, participants could manually initiate additional measurements.   
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Table S4.  International Classification of Disease Coding and Number of Endpoints in 11,596 Participants.   
Endpoint*  
 ICD Codes by Version   Nº of Endpoints  
 8  9  10   All  Fatal  Nonfatal†  
Total mortality§       2821  2821   
Cardiovascular mortality§   390-448  390.0-459.9  I00-I79, R96   1059  1059   
Noncardiovascular mortality       1573  1573   
Cause unknown       144  144   
All cardiovascular endpoints‡       2034    
Coronary endpoints§       916  262   
Myocardial infarction   410  410  I21-I22   663  227  444  
Coronary revascularization   …  …  …   179   179  
Death from ischemic heart disease   411-412  411-414  I20, I24-I25   154  154   
Sudden death   427.2, 795  427.5, 798  I46, R96   83  83    
Heart failure   427.0, 427.1 
427.2, 429, 519.1, 
782.4  
429  I50, J81   685  148  596  
Stroke§   430-434, 436  430-434, 436  I60-I68   809  279  670  
* The median follow-up of 11,596 participants was 13.6 years (5th to 95th percentile interval, 3.6–26.0 years).  The number of person-years of follow-up totaled 
158,431. 
†   The nonfatal events do not add up, because within each category only the first event was analyzed.   
‡ Primary endpoint.   
§ Secondary endpoint.   
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Table S5.  Baseline Characteristics of Participants by Fourths of the Distribution of 24-Hour Mean Arterial 
Pressure.  
Baseline Characteristics  
Statistics 
<83 mm Hg  
(n=2899)  
83-89 mm Hg  
(n=2899)  
90-96 mm Hg  
(n=2899)  
≥97 mm Hg  
(n=2899)  
P Value*  
Participants with characteristic       
Women — no. (%)  2016 (69.5)  1481 (51.1)  1190 (41.1)  1067 (36.8)  <0.001  
Europeans — no. (%)  1682 (58.0)  1867(64.4)  1859 (64.1)  1688 (58.2)  0.932  
Asians — no. (%)  643 (22.2)  516 (17.8)  516 (18.0)  638 (22.0)  0.991  
South Americans — no. (%)  574 (19.8)  516 (17.8)  518 (17.9)  573 (20.0)  0.925  
Current smoking — no. (%)†‡   720 (24.8)  781 (26.9)  837 (28.9)  812 (28.0)  0.001  
Drinking alcohol — no. (%)†§   1111 (38.3)  1451 (50.1)  1640 (56.6)  1804 (62.2)  <0.001  
Office hypertension — no. (%)¶ǁ   831 (28.7)  1637 (56.5)  2226 (76.8)  2741 (94.6)  <0.001  
On antihypertensive treatment — no. (%)†   283 (9.8)  441 (15.2)  588 (20.3)  961 (33.2)  <0.001  
Diabetes mellitus — no. (%)**  138 (4.8)  180 (6.2)  232 (8.0)  335 (11.6)  <0.001  
History of cardiovascular disease — no. (%)†  213 (7.4)  269 (9.3)  357 (12.3)  448 (15.5)  <0.001  
Mean (±SD) of characteristic       
Age—yr  45.8±16.4  50.8±16.4  55.1±14.9  59.5±12.4  <0.001  
Body mass index— kg/m2†† 23.9±4.0  25.2±4.2  26.0±4.4  26.6±4.3  <0.001  
Office systolic blood pressure — mm Hgǁ   116.4±16.4  126.8±17.3  135.5±19.9  151.7±23.6  <0.001  
Office diastolic blood pressure — mm Hgǁ   71.0±8.7  76.9±9.1  81.3±9.8  90.0±11.7  <0.001  
Office mean arterial pressure — mm Hgǁ  86.1±9.9  93.6±10.2  99.3±11.4  110.6±13.8  <0.001  
24-Hour systolic blood pressure — mm Hg‡‡  108.5±6.0  118.07±5.5  126.3±6.5  141.4±11.9  <0.001  
24-Hour diastolic blood pressure — mm Hg‡‡   64.6±3.7  70.5±2.8  75.6±3.3  84.9±6.86  <0.001  
24-Hour mean arterial pressure — mm Hg‡‡   79.3±3.2  86.3±1.7  92.4±2.0  103.7±7.0 <0.001  
24-Hour heart rate — beats per minute  72.0±8.8  72.2±9.1  72.4±9.3  73.5±10.0  <0.001  
Serum cholesterol, mg/dL§§  205.0±42.5  213.1±43.6  220.1±44.8  220.8±43.6  <0.001  
Blood glucose, mg/dL§§  89.3±21.4   92.9±23.2  94.6±27.3  93.2±30.4  <0.001  
* P values are for linear trend across categories.   
† Assessed by questionnaire or interview at baseline.   
‡ Use of smoking materials on a daily basis.   
§ Occasional or daily consumption of alcoholic beverages.   
¶ An office blood pressure of ≥130 mm Hg systolic or ≥80 mm Hg diastolic, or use of antihypertensive drugs.   
ǁ Office blood pressure was measured using standard mercury sphygmomanometers or validated auscultatory or 
oscillometric devices.  Mean arterial pressure was diastolic blood pressure plus one third of pulse pressure (the 
difference between systolic and diastolic blood pressure).   
** Use of antidiabetic drugs, fasting blood glucose of ≥126 mg/dL (7.0 mmol/l), random blood glucose of ≥200 mg/dL 
(11.1 mmol/l), a self-reported diagnosis, or diabetes documented in practice or hospital records.     
†† Body weight in kilogram divided by body height in meters squared.   
‡‡ 24-Hour blood pressure was measured with validated oscillometric devices (see Table S3).   
§§ Serum cholesterol and blood glucose were measured by automated methods in certified laboratories.  Conversion 
factors: To convert cholesterol to mmol/l, multiply by 0.0259, to convert glucose to mmol/l, multiply by 0.056.   
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Table S6.  Correlation Matrix between Blood Pressure Indexes.   
BP Item‡  
24-Hour Ambulatory BP*   Office BP†  
Systolic  Diastolic  MAP  Systolic  Diastolic  MAP  
24–Hour systolic BP  ─       
24–Hour diastolic BP  0.73  ─      
24–Hour MAP  0.92  0.94  ─     
Office systolic BP  0.67  0.46  0.60  ─    
Office diastolic BP  0.53  0.62  0.62  0.68  ─   
Office MAP  0.65  0.60  0.67  0.91  0.92  ─  
* Validated oscillometric devices, used for ambulatory blood pressure (BP) monitoring, measured mean arterial 
pressure (MAP) and extrapolated systolic and diastolic BP, using proprietary algorithms with an accuracy of ±5 
mm Hg against the auscultatory standard.   
† In those cohort that observers applied the auscultatory or oscillometric method to measure BP levels, the systolic and 
diastolic BP were set to the nearest even number.  Office MAP was computed as diastolic BP plus one third of pulse 
pressure (difference between systolic and diastolic BP).   
‡ All correlation coefficients were highly significant (P<0.0001).   
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Table S7.  24-Hour Mean Arterial Pressure Thresholds Yielding Equivalent 10-Year Risk for All 
Cardiovascular Events Compared to the Reference Thresholds of Office Mean Arterial Pressure in 11,596 
Participants by Difference Baseline Clinical Characteristics.  
Baseline Clinical Characteristics 
 Reference Office MAP*  
Thresholds and  
Associated 10-Year Risk  
 24-Hour Ambulatory MAP* 
Thresholds Yielding  
Equivalent 10-Year Risk†  Proposed   
Thresholds§ 
Type  E/AR‡  
Level  
(mm Hg) 
Risk in Percent  
(95% CI)  
 Point Estimates  
(95% CI)†  
Women  626/5754   93  2.66 (2.18-3.13)   88.8 (87.4-90.1)  88  
  97  2.84 (2.34-3.33)   90.7 (90.0-91.5)  90  
  107  3.34 (2.75-3.93)   95.7 (94.2-97.1)  96  
Men  1408/5842   93  5.93 (5.05-6.82)   90.2 (88.4-92.0)  90  
  97  6.26 (5.35-7.18)   92.4 (91.0-93.7)  92  
  107  7.17 (6.11-8.23)   97.7 (97.0-98.5)  98  
Cardiovascular 
disease 
456/1287   93  17.6 (14.5-20.7)   87.6 (83.7-91.5)  88  
  97  18.3 (15.2-21.4)   89.8 (87.2-92.5)  90 
  107  20.2 (16.9-23.6)   95.4 (94.0-96.8)  96  
Free of 
cardiovascular 
disease  
1578/10,309   93  3.68 (3.25-4.10)   89.6 (88.5-90.6)  90  
  97  3.92 (3.47-4.37)   91.6 (91.0-92.2)  92  
  107  4.61 (4.05-5.17)   96.8 (95.9-97.7)  96  
Diabetic participants  299/885   93  17.8 (14.4-21.1)   91.0 (87.9-94.3)  90  
  97  18.5 (15.3-21.8)   92.5 (90.2-94.8)  92  
  107  20.6 (17.3-23.8)   96.0 (95.1-96.9)  96  
Nondiabetic 
participants  
1735/10,711   93  3.92 (3.49-4.35)   89.3 (88.3-90.3)  90  
  97  4.15 (3.71-4.60)   91.5 (90.9-92.0)  92  
  107  4.80 (4.26-5.35)   96.8 (96.0-97.7)  96  
16-6 day/nighttime 
BP readings   
1870/10,333   93  4.52 (4.04-4.99)   89.4 (88.5-90.3)  90  
  97  4.80 (4.31-5.29)   91.5 (90.9-92.0)  92  
  107  5.58 (5.00-6.17)   96.7 (95.9-97.4)  96  
11-5 day/nighttime 
BP readings  
1984/11,171   93  4.55 (4.09-5.00)   89.5 (88.4-90.5)  90  
  97  4.82 (4.34-5.29)   91.5 (90.8-92.2)  92  
  107  5.57 (4.98-6.15)   96.6 (95.9-97.4)  96  
Untreated  1226/9323   93  2.98 (2.62-3.34)   89.4 (88.5-90.3)  90  
  97  3.21 (2.83-3.59)   91.7 (91.1-92.2)  92  
  107  3.85 (3.37-4.33)   97.3 (96.2-98.4)  98  
Treated  808/2273   93  18.3 (16.1-20.5)   90.1 (86.8-93.4)  90  
  97  18.9 (16.8-20.9)   91.8 (89.4-94.2)  92  
  107  20.5 (18.5-22.5)   95.9 (95.3-96.5)  98  
* MAP indicates mean arterial pressure, which was estimated from office blood pressure (MAP = diastolic blood pressure plus one third of the 
difference between systolic and diastolic blood pressure, or measured using oscillometric ambulatory monitors).  Oscillometric devices 
compute systolic and diastolic blood pressure, using proprietary algorithms (Figure 1 in the Supplemental Data).   
† The 24─hour MAP thresholds were computed by bootstrapping 1000 times multivariable-adjusted Cox models.   
‡ E/AR denotes the number of endpoints/number of participants at risk according to baseline clinical categories.   
§ Proposed thresholds were obtained by rounding the point estimates to the closest even integer value which were set at 88, 90, 92, 96, and 
98 mm Hg reasons of consistency and precaution.  The so obtained thresholds were similar among baseline clinical categories.   
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Table S8.  24-Hour Mean Arterial Pressure Thresholds Yielding Equivalent 10-Year Risk for All 
Cardiovascular Events Compared to the Reference Thresholds of Office Mean Arterial Pressure in 
Participants by Excluding Cohorts.   
Cohorts exclusion  
(n° of endpoints/participants at 
risk)  Level  
(mm Hg)‡  
Risk in Percent (95% CI) 
Proposed   
Thresholds‡  
Reference Office MAP*  
Thresholds and 
associated 10-Year Risk  
24-Hour Ambulatory MAP* 
Thresholds Yielding 
Equivalent 10-Year Risk†  
Without Ohasama (315/1326)  93  4.29 (3.85-4.73)  89.1 (88.0-90.2)  90  
97  4.55 (4.10-5.00)  91.4 (90.6-92.1)  92  
107  5.28 (4.75-5.81)  97.0 (96.3-97.7)  96  
Without JingNing  (42/855)  93  4.53 (4.11-4.96)  89.2 (88.3-90.1)  90  
97  4.78 (4.34-5.22)  91.2 (90.7-91.7)  92  
107  5.47 (4.94-5.99)  96.3 (95.5-97.1)  96  
Without EPOGH  (54/1456)  93  5.44 (4.92-5.97)  89.4 (88.4-90.5)  90  
97  5.75 (5.22-6.27)  91.4 (90.8-92.1)  92  
107  6.58 (6.00-7.16)  96.5 (95.8-97.2)  96  
Without Noordkempen  (280/1436)  93  4.85 (4.33-5.36)  89.7 (88.7-90.7)  90  
97  5.13 (4.60-5.66)  91.7 (91.1-92.4)  92  
107  5.90 (5.27-6.52)  96.9 (96.2-97.6)  96  
Without Uppsala  (683/1110)  93  3.82 (3.44-4.20)  89.9 (89.1-90.7)  90  
97  4.06 (3.66-4.46)  91.8 (91.2-92.3)  92  
107  4.72 (4.24-5.21)  96.4 (95.7-97.1)  96  
Without Copenhagen  (366/2148)  93  4.22 (3.71-4.73)  89.1 (87.9-90.3)  90  
97  4.45 (3.93-4.98)  91.1 (90.4-91.9)  90  
107  5.10 (4.50-5.70)  96.2 (95.4-96.9)  96  
Without Dublin  (19/946)  93  5.49 (4.99-5.99)  89.5 (88.5-90.4)  90  
97  5.80 (5.28-6.32)  91.5 (90.9-92.0)  92  
107  6.65 (6.06-7.24)  96.4 (95.8-97.1)  96  
Without Maracaibo  (130/590)  93  4.06 (3.65-4.47)  89.2 (88.3-90.2)  90  
97  4.33 (3.91-4.75)  91.5 (90.9-92.0)  92  
107  5.07 (4.58-5.56)  97.0 (96.2-97.7)  98  
Without Montevideo  (145/1729)  93  4.57 (4.10-5.03)  89.5 (88.6-90.4)  90  
97  4.85 (4.36-5.33)  91.6 (91.0-92.1)  92  
107  5.61 (5.04-6.19)  96.8 (96.0-97.5)  96  
* MAP indicates mean arterial pressure, which was estimated from office blood pressure (MAP = diastolic blood pressure plus one third of 
the difference between systolic and diastolic blood pressure, or measured using oscillometric ambulatory monitors).  Oscillometric 
devices compute systolic and diastolic blood pressure, using proprietary algorithms (Figure 1 in the Supplemental Data).   
† The 24-hour MAP thresholds were computed by bootstrapping 1000 times multivariable-adjusted Cox models.   
‡ Proposed thresholds were obtained by rounding the point estimates to the closest even integer value. The so obtained thresholds were 
similar across subgroups.   
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Table S9.  24-Hour Mean Arterial Pressure Thresholds Yielding Equivalent 10-Year Risk as Reference Thresholds of Office Mean Arterial 
Pressure in Europeans or in Asians and South Americans.   
  Endpoints   
Reference Office MAP*  
Thresholds and Associated  
10-Year Risk  
 
24-Hour Ambulatory MAP* Thresholds  
Yielding Equivalent 10-Year Risk†   
Type   
No.   
E/ASA‡  
 Risk in Percent  
(95% CI)  
 Point Estimates  
(95% CI)†  Proposed   
Thresholds  
E/ASA‡§   
Level  
(mm Hg)  
Europeans  
(n=7096)  
Asians and  
South Americans  
(n=4500)  
 
Europeans  
(n=7096)   
Asians and  
South Americans  
(n=4500)  
All cardiovascular 
endpoints   
1402/323   93  3.41 (2.97-3.85)  6.48 (5.56-7.40)   88.6 (87.4-89.7)  90.4 (88.7-92.1)  88/90  
  97  3.65 (3.19-4.10)  6.82 (5.86-7.77)   91.2 (90.6-91.9)  92.0 (90.8-93.1)  92/92  
  107  4.31 (3.77-4.85)  7.75 (6.61-8.90)   97.9 (96.9-99.0)  95.9 (95.1-96.7)  98/96  
Total mortality  1899/922   93  2.83 (2.43-3.23)  5.53 (4.56-6.50)   88.9 (87.0-90.8)  89.8 (87.0-92.6)  88/88  
  97  2.92 (2.52-3.32)  5.72 (4.74-6.70)   91.4 (90.7-92.1)  91.6 (89.7-93.5)  92/92  
  107  3.15 (2.71-3.58)  6.24 (5.19-7.28)   97.7 (95.2-100.2)  96.1 (94.9-97.3)  96/96  
Cardiovascular 
mortality  
701/358   93  0.67 (0.49-0.85)  2.01 (1.47-2.55)   89.2 (87.3-91.1)  91.2 (88.0-94.4)  90/92  
  97  0.71 (0.53-0.90)  2.12 (1.56-2.68)   91.7 (90.6-92.8)  92.9 (90.5-95.3)  92/92  
  107  0.84 (0.63-1.05)  2.43 (1.79-3.07)   98.0 (96.5-99.4)  97.0 (95.6-98.4)  98/98  
Coronary 
endpoints  
688/228   93  1.84 (1.55-2.14)  3.15 (2.46-3.84)   89.2 (87.2-91.1)  89.6 (82.8-96.4)  90/90  
  97  1.94 (1.64-2.25)  3.22 (2.53-3.91)   91.7 (90.7-92.6)  91.8 (86.5-95.1)  92/92  
  107  2.22 (1.85-2.59)  3.40 (2.65-4.15)   97.0 (95.0-98.9)  93.8 (91.2-96.5)  96/94  
Stroke  493/316   93  1.14 (0.86-1.41)  2.67 (2.08-3.27)   89.8 (87.3-90.3)  90.3 (88.3-92.3)  90/90  
  97  1.23 (0.93-1.53)  2.92 (2.27-3.56)   91.4 (90.6-92.1)  92.3 (90.9-93.6)  92/92  
  107  1.50 (1.11-1.89)  3.62 (2.74-4.50)   97.8 (96.4-99.2)  97.2 (96.1-98.2)  98/98  
* MAP indicates mean arterial pressure, which was estimated from office blood pressure (MAP = diastolic blood pressure plus one third of the difference between systolic and diastolic blood 
pressure) or measured by oscillometric ambulatory monitors.  Oscillometric devices compute systolic and diastolic blood pressure, using proprietary algorithms (Figure 1 in the Supplemental 
Data).   
† The 24─hour MAP thresholds were computed by bootstrapping 1000 times multivariable-adjusted Cox.   
‡ E/ASL refers to the number of endpoints or the proposed thresholds in participants enrolled in Europe or in Asia and South America.   
§ Proposed thresholds were obtained by rounding the point estimates to the closest even integer value.  The so obtained thresholds were similar between Europeans and Asians and South 
Americans.   
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Table S10.  Incidence of Primary and Secondary Endpoints by Increasing Categories of 24-Hour Mean Arterial Pressure.    
Endpoints  
Normotension  
(<90 mm Hg)  
Elevated  
Blood Pressure  
(≥90 to <92 mm Hg)   
Stage-1 Hypertension 
(≥92 to <96 mm Hg)  
Stage-2 and Severe 
Hypertension  
(≥96 mm Hg)   
No. at risk  [11,596]  6183 909  1544  2960  
Primary endpoint      
Endpoints — no. (%) [2034]  715  134  312  873  
Rate per 1000 person-years  11.9 (11.1-13.2)  11.3 (9.5-13.6)  15.2 (13.5-17.2)  21.5 (20.0-23.3)  
Secondary endpoints      
Total mortality      
Deaths — no. (%) [2821]  1107  215  450  1049  
Rate per 1000 person-years  17.2 (16.2-18.6)  16.8 (14.6-19.4)  19.4 (17.7-21.5)  22.6 (21.2-24.3)  
Cardiovascular mortality      
Deaths — no. (%) [1059]  358  62  165  474  
Rate per 1000 person-years  5.6 (5.1-6.6)  4.9 (3.7-6.5)  7.0 (6.0-8.5)  10.0 (9.1-11.3)  
Coronary endpoints      
Endpoints — (%) [916]  322  64  132  398  
Rate per 1000 person-years  5.2 (4.7-6.2)  5.0 (3.9-6.7)  6.0 (5.0-7.4)  8.7 (7.8-10.0)  
Stroke      
Endpoints — no. (%) [809]  278  41  135  355  
Rate per 1000 person-years  4.3 (3.8-5.2)  3.3 (2.3-4.7)  6.2 (5.2-7.6)  8.4 (7.4-9.7)  
Rates were standardized by the direct method for cohort, sex and age (<40, 40 to <60, ≥60 years).  P values for linear trend in the rates (given with 
95% confidence interval) across the blood pressure categories were all <0.001.   
Page S12 of S17  
 
Table S11.  Nested Cox Models Relating the Primary Endpoint to 24-Hour Blood Pressure Level.   
Models  2 Statistic  P Value  R2
 
(%)†  
Base model*   3173.53  <0.001   
+ 24-hour systolic BP  3329.89  <0.001  1.34  
+ 24-hour diastolic BP  3279.16  <0.001  0.91  
+ 24-hour mean arterial pressure  3322.98  <0.001  1.28‡  
Base model including also 24-hour systolic BP‡      
+ 24-hour mean arterial pressure  3334.03  0.042  0.04‡  
Base model including also 24-hour diastolic BP‡     
+ 24-hour mean arterial pressure  3334.04  <0.001  0.47‡  
Base model including also 24-hour systolic and 24-hour diastolic BP‡      
+ 24-hour mean arterial pressure  3334.04  1.000  0.000‡  
* Accounts for cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and 
drinking, serum cholesterol, antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus.   
† R2 is an estimate of the additional variance explained 
(https://apha.confex.com/apha/134am/techprogram/paper_135906.htm).  
‡ R2 for adding mean arterial pressure to models.    
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Table S12.  Nested Cox Models Relating the Primary Endpoint to 24-Hour Blood Pressure Categories.   
Models  2 Statistic  P Value  R2
 
(%)†  
Base model*   3173.53  <0.001   
+ 24-hour systolic BP ≥125 mm Hg  3256.52  <0.001  0.71  
+ 24-hour diastolic BP ≥75 mm Hg  3241.57  <0.001  0.58  
+ 24-hour mean arterial pressure BP ≥92 mm Hg  3277.65  <0.001  0.89‡  
Base model including also 24-hour systolic BP ≥125 mm Hg‡     
+ 24-hour mean arterial pressure BP ≥92 mm Hg  3286.14  <0.001  0.25‡  
Base model including also 24-hour diastolic BP ≥75 mm Hg‡     
+ 24-hour mean arterial pressure BP ≥92 mm Hg  3278.85  <0.001  0.32‡  
Base model including also 24-hour systolic BP ≥125 mm Hg  
and 24-hour diastolic BP ≥75 mm Hg‡   
   
+ 24-hour mean arterial pressure BP ≥92 mm Hg  3287.81  <0.001  0.10‡  
* Accounts for cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and 
drinking, serum cholesterol, antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus.   
† R2 is an estimate of the additional variance explained 
(https://apha.confex.com/apha/134am/techprogram/paper_135906.htm).  
‡ R2 for adding mean arterial pressure to models.    
Page S14 of S17  
 
 
 
 
Figure S1  
Pressure Oscillations in a Sphygmomanometer Cuff During Deflation.  
Upper trace, Korotkoff sounds; second trace, cuff pressure; third trace, oscillations in cuff pressure.  The 
maximal oscillation occurs at a pressure of 108 mm Hg, the mean arterial pressure.  Bottom trace, radial 
pulse.  Reproduced with permission from Curr Opin Nephrol Hypertens. 1993;2:380–385.  
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Figure S2  
Heat Map Depicting the 10-Year Risk of a Primary Endpoint in Relation to 24-Hour Mean Arterial 
Pressure and Pulse Pressure in 11,596 Participants.  
Numbers in the Panels A grid represent the percentage of participants within each blood pressure 
cross-classification category; numbers in Panel B represent the 10-year risk.  The heat map was 
derived by Cox proportional hazards regression with pulse pressure plotted along the vertical axis and 
mean arterial pressure (MAP) along the horizontal axis.  Estimates of the 10-year risk were 
standardized to the average of the distributions in the whole study population (mean or ratio) of all 
covariables.  Higher MAP conferred greater risk (P<0.001) with an additional contribution of pulse 
pressure (P<0.001).   
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